William Baird Net Worth

The estimated Net Worth of William D Iii Baird is at least $9.78 Millón dollars as of 16 February 2021. Mr. Baird owns over 693 units of Bluebird bio Inc stock worth over $20,607 and over the last 13 years he sold BLUE stock worth over $559,232. In addition, he makes $9,199,920 as Chief Financial Officer at Bluebird bio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Baird BLUE stock SEC Form 4 insiders trading

William has made over 17 trades of the Bluebird bio Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 693 units of BLUE stock worth $19,515 on 16 February 2021.

The largest trade he's ever made was exercising 40,000 units of Bluebird bio Inc stock on 12 October 2017 worth over $570,000. On average, William trades about 5,271 units every 57 days since 2012. As of 16 February 2021 he still owns at least 35,529 units of Bluebird bio Inc stock.

You can see the complete history of Mr. Baird stock trades at the bottom of the page.

William Baird biography

William D. Baird III serves as Chief Financial Officer of the Company. Mr. Baird has served as our Chief Financial Officer since February 2019 and our Principal Financial Officer since March 2019. Mr. Baird served as Chief Financial Officer of Amicus Therapeutics, Inc. from April 2012 until December 2018. From April 2005 until April 2012, Mr. Baird served as Chief Financial Officer of PTC Therapeutics, Inc. (“PTC”). Before that, Mr. Baird held various positions of increasing responsibility with PTC from 2002 to 2005. Mr. Baird previously worked in the life science practice at L.E.K. Consulting, a strategy consulting firm, from 1999 to 2002, and at First Union National Bank as a corporate underwriter from 1994 to 1997. Since June 2018, Mr. Baird has served on the Board of Directors of Axcella Health, a biotechnology company. Mr. Baird received a B.S. from Georgetown University’s Edmund A. Walsh School of Foreign Service, and an M.B.A. from The Wharton School of the University of Pennsylvania.

What is the salary of William Baird?

As the Chief Financial Officer of Bluebird bio Inc, the total compensation of William Baird at Bluebird bio Inc is $9,199,920. There are 1 executives at Bluebird bio Inc getting paid more, with Nick Leschly having the highest compensation of $13,153,600.

How old is William Baird?

William Baird is 48, he's been the Chief Financial Officer of Bluebird bio Inc since 2019. There are 14 older and 5 younger executives at Bluebird bio Inc. The oldest executive at Bluebird bio Inc is Wendy Dixon, 64, who is the Independent Director.

What's William Baird's mailing address?

William's mailing address filed with the SEC is C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.

Insiders trading at Bluebird bio Inc

Over the last 11 years, insiders at Bluebird bio Inc have traded over $130,743,125 worth of Bluebird bio Inc stock and bought 6,469 units worth $399,874 . The most active insiders traders include Steven Gillis, John Maraganore y Robert I Tepper. On average, Bluebird bio Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,033. The most recent stock trade was executed by Thomas J Klima on 3 June 2024, trading 3,834 units of BLUE stock currently worth $3,719.

What does Bluebird bio Inc do?

we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.

Complete history of Mr. Baird stock trades at Amicus Therapeutics Inc, Bluebird bio Inc y Axcella Health Inc

Bluebird bio Inc executives and stock owners

Bluebird bio Inc executives and other stock owners filed with the SEC include:

• Nick Leschly,
  President, Chief Executive Officer, Director
• William Baird,
  Chief Financial Officer
• David Davidson,
  Chief Medical Officer
• Philip Gregory,
  Chief Scientific Officer
• Jason Cole,
  Chief Operating Officer and Legal Officer, Secretary
• Nick Leschly,
  Pres & Director
• William Sellers,
  Independent Director
• William D. Baird III,
  Principal Financial & Accounting Officer
• Daniel Lynch,
  Independent Chairman of the Board
• Jason F. Cole Esq.,
  Chief Strategy & Financial Officer
• Thomas J. Klima,
  Chief Commercial Officer & COO
• Mark Vachon,
  Independent Director
• David Schenkein,
  Independent Director
• Wendy Dixon,
  Independent Director
• John Agwunobi,
  Independent Director
• Ingrid Goldberg,
  VP, Investor Relations
• Denice Torres,
  Director
• Joanne Smith-Farrell,
  Chief Business Officer
• Alison Finger,
  Chief Commercial Officer
• Katy Burnett,
  Interim Principal Accounting Officer
• Richard Colvin M.D., Ph.D.,
  Chief Medical Officer
• Andrea Walton,
  Chief People Officer
• Katherine Edna Breedis C.F.A., CMT,
  Interim CFO, Principal Financial Officer & Principal Accounting Officer
• Anne-Virginie Eggimann M.Sc.,
  Chief Regulatory Officer
• Melissa Bonner,
  Sr. VP of Research
• Dr. Liviu Niculescu M.D., Ph.D.,
  Sr. VP of Global Medical Affairs
• Sarah Alspach,
  Chief Communications Officer
• Kathleen A. Wilkinson,
  Chief People Officer
• Elizabeth Pingpank,
  Director of Corp. Communications
• Helen C. Fu,
  Sr. VP, Gen. Counsel & Sec.
• Jessica Whitten,
  VP, Global Controller & Chief Accounting Officer
• Kasra Kasraian,
  Sr. VP of Technical Devel. & Operations
• Gina R. Consylman CPA,
  Chief Financial Officer
• Andrew Obenshain,
  Pres, CEO & Director
• John Maraganore,
  Director
• James Mandell,
  Director
• Susanna Gatti High,
  Chief Operating Officer
• Eric Sullivan,
  Principal Accounting Officer
• Andrew Obenshain,
  President and CEO
• Douglas Melton,
  
• Mary Lynne Hedley,
  Director
• Kory James Wentworth,
  Principal Accounting Officer
• Thomas J Klima,
  See Remarks
• Charlotte Jones Burton,
  
• Axel Polack,
  Director
• Geert Jan Mulder,
  Director
• Christopher Krawtschuk,
  Chief Financial Officer
• Mitchell H. Finer,
  Chief Scientific Officer
• James M. Detore,
  Chief Financial Officer
• Venture Fund Vii Lparch Ven...,
  
• Robert I Tepper,
  Director
• Rock Ventures Lptrv Gp, Llc...,
  
• Linda Bain,
  VP, Fin. & Business Operations
• Rock Ventures Lp Third Rock...,
  
• Jeffrey T. Walsh,
  Chief Strategy Officer
• Steven Gillis,
  Director
• Richard A. Paulson,
  
• Gina Consylman,
  Chief Financial Officer
• Anne Virginie Eggimann,
  Chief Regulatory Officer
• Jessica Whitten,
  Chief Accounting Officer
• Marcela V. Maus,
  Director
• Sarah Js Glickman,
  Director
• Ramy Ibrahim,
  Director
• Joseph Vittiglio,
  Chief Business & Legal Officer
• Richard A Colvin,
  Chief Medical Officer
• Najoh Tita Reid,
  
• Elisabeth Leiderman,
  
• Michael Cloonan,
  
• O. James Sterling,
  Chief Financial Officer